Department of Clinical Research, Regional Research Institute for Homoeopathy, Hyderabad, Telangana, India.
Department of Clinical Research, Central Council for Research In Homoeopathy, New Delhi, India.
Homeopathy. 2024 Feb;113(1):32-40. doi: 10.1055/s-0043-1762591. Epub 2023 Apr 4.
Globally, adenotonsillar hypertrophy (ATH) is one of the most prevalent upper respiratory tract disorders of children, with associated troublesome symptoms such as sleep apnea and cognitive disturbances. In this study, we evaluated the potential role of individualized homeopathic medicines in the management of symptomatic ATH in children.
A multicenter prospective observational study was conducted at five institutes under the Central Council for Research in Homoeopathy, India. Primary and secondary outcomes (symptom score for adenoids, other symptoms of ATH, Mallampati score, tonsillar size, Sleep-Related Breathing Disorder of the Paediatric Sleep Questionnaire [SRBD-PSQ]) were assessed through standardized questionnaires at baseline and at 3, 6, 9 and 12 months. Radiological investigations for assessing the adenoid/nasopharyngeal (A/N) ratio were carried out at baseline, 6 and 12 months. All analyses were carried out using an intention-to-treat approach.
A total of 340 children were screened and 202 children suffering from ATH were enrolled and followed up monthly for 12 months. Each patient received individualized homeopathic treatment based on the totality of symptoms. Statistically significant reductions in adenoid symptom score, Mallampati score (including tonsillar size), SRBD-PSQ sleep quality assessment and A/N ratio were found over time up to 12 months ( < 0.001). Homeopathic medicines frequently indicated were . No serious adverse events were recorded during the study period.
This study suggests that homeopathic medicines may play a beneficial role in the management of symptomatic ATH in children. Well-designed comparative trials are warranted.
在全球范围内，腺样体扁桃体肥大（ATH）是儿童最常见的上呼吸道疾病之一，伴有睡眠呼吸暂停和认知障碍等麻烦症状。在这项研究中，我们评估了个体化顺势疗法药物在儿童有症状 ATH 管理中的潜在作用。
在印度中央顺势疗法研究理事会的五个机构中进行了一项多中心前瞻性观察性研究。通过标准化问卷在基线和 3、6、9 和 12 个月评估主要和次要结局（腺样体症状评分、ATH 的其他症状、Mallampati 评分、扁桃体大小、儿童睡眠呼吸障碍问卷的睡眠相关呼吸障碍评分 [SRBD-PSQ]）。基线、6 和 12 个月进行了评估腺样体/鼻咽（A/N）比值的放射学检查。所有分析均采用意向治疗方法进行。
共筛选了 340 名儿童，纳入了 202 名患有 ATH 的儿童，并每月随访 12 个月。每位患者根据症状的整体情况接受个体化顺势疗法治疗。随着时间的推移，腺样体症状评分、Mallampati 评分（包括扁桃体大小）、SRBD-PSQ 睡眠质量评估和 A/N 比值均有统计学意义的降低，持续至 12 个月（<0.001）。经常指示的顺势疗法药物为. 在研究期间未记录到严重不良事件。
这项研究表明，顺势疗法药物可能在儿童有症状 ATH 的管理中发挥有益作用。需要进行精心设计的对照试验。
